J&J OTC Brands Regain Market Share
This article was originally published in The Tan Sheet
Evidence of J&J’s U.S. OTC sales turnaround includes Children’s Tylenol, Children’s Motrin and Zyrtec as top sellers behind private label products in their categories and Tylenol sales growing more than 20% during the 12 weeks ending June 16, according to market research firm IRI’s data.
You may also be interested in...
A lack of regulatory harmonization for dietary supplements in Asia is a big challenge facing companies operating in the region, according to experts from the Asia Regulatory Professionals Association. The ARPA is looking to start a conversation on the issue which the association hopes will lead to regulatory change.
The Chinese Society of Clinical Oncology (CSCO) annual meeting, against the background of the global pandemic, has one clear message that local researchers and players are pressing ahead to take a leadership role in cutting-edge cancer research globally.
Company is confident that data readout from pivotal trial could be ready before the end of 2020.